Preventing Pancreatic Beta Cell Degeneration
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for type I diabetes lack effective methods to prevent pancreatic beta cell degeneration, which is a hallmark of the disease, leading to insulin deficiency and elevated blood glucose levels.
Innovation Solution
Development of compositions and formulations comprising specific compounds of Formulas I-XI, or their pharmaceutically acceptable salts and prodrugs, which are administered to prevent pancreatic beta cell degeneration and treat type I diabetes by inhibiting the progressive loss of insulin-producing cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments for type I diabetes are used, then blood glucose levels can be managed, but pancreatic beta cell degeneration continues to progress
Solution Approach 1:
The patent applies preliminary action by administering compounds of Formulas I-XI before complete beta cell destruction occurs. The compounds prevent degeneration by inhibiting apoptotic pathways and oxidative stress, thereby preserving beta cell function before the disease progresses to irreversible damage. This is demonstrated in db/db mice where treatment prevented the progressive loss of insulin-producing cells.
Solution Approach 2:
The patent uses intermediary mechanisms by employing compounds that act as mediators between external therapeutic agents and internal beta cell protection. These compounds (Formulas I-XI) serve as intermediaries that transmit protective signals to beta cells, reducing apoptosis and oxidative stress, thereby preventing degeneration without directly replacing the cells.
2Reliability
If pancreatic beta cell degeneration is prevented, then insulin production is maintained, but no effective treatment currently exists
Solution Approach 1:
The patent applies parameter changes by modifying chemical structures to create compounds with specific therapeutic properties. The compounds of Formulas I-XI are designed with specific molecular parameters (functional groups, molecular weight, lipophilicity) that enable them to cross cell membranes and activate protective pathways in beta cells, thereby maintaining insulin production.
Solution Approach 2:
The patent employs composite material principles by combining multiple functional groups within the compound structures (Formulas I-XI). These composite molecular structures integrate antioxidant, anti-apoptotic, and insulin-preserving activities, creating a multi-functional therapeutic agent that addresses multiple aspects of beta cell protection simultaneously.
Data Source
AI summary
The present invention relates to compounds and pharmaceutically acceptable salts thereof and formulations comprising the compounds or a pharmaceutically acceptable salts thereof that are useful in methods of preventing pancreatic beta cell degeneration or methods of treating a disorder associated with pancreatic beta cell degeneration, such as type I diabetes.